07.12.2023 22:05:00
|
Haemonetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 7, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 9:45am Pacific time.
The public may access Mr. Simon's presentation live via audio webcast at:
https://jpmorgan.metameetings.net/events/healthcare24/sessions/49347-haemonetics-corporation/webcast?gpu_only=true&kiosk=true
The live webcast can also be accessed under the Events & Presentations section of the Company's Investor Relations website. The replay of the presentation will be available for 30 days using the link provided above and on Investor Relations website shortly after the live event.
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Sr. Director-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
olga.guyette@haemonetics.com | david.trenk@haemonetics.com |
Media Contact: |
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-to-present-at-42nd-annual-jp-morgan-healthcare-conference-302009459.html
SOURCE Haemonetics Corporation
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Haemonetics Corp.mehr Nachrichten
22.01.25 |
Erste Schätzungen: Haemonetics stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) | |
07.08.24 |
Ausblick: Haemonetics öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) |
Analysen zu Haemonetics Corp.mehr Analysen
Aktien in diesem Artikel
Haemonetics Corp. | 66,00 | 2,33% |